Literature DB >> 2514319

Metabolism of D-ribose administered continuously to healthy persons and to patients with myoadenylate deaminase deficiency.

M Gross1, S Reiter, N Zöllner.   

Abstract

D-ribose was administered orally or intravenously over at least 5 h to eight healthy volunteers and five patients with myoadenylate deaminase deficiency. Intravenous administration rates were 83, 167, and 222 mg/kg/h, which were well tolerated but oral administration of more than 200 mg/kg/h caused diarrhea. The average steady state serum ribose level ranged between 4.8 mg/100 ml (83 mg/kg/h, oral administration) and 81.7 mg/100 ml (222 mg/kg/h, intravenous administration). Serum glucose level decreased during ribose administration. The intestinal absorption rate of orally administered ribose was 87.8%-99.8% of the intake at doses up to 200 mg/kg/h without first pass effect. Urinary losses were 23% of the intravenously administered dose at 222 mg/kg/h. Ribose appeared to be excreted by glomerular filtration without active reabsorption; a renal threshold could not be demonstrated. The amount of ribose transported back from the tubular lumen depended on the serum ribose level. There was no difference in ribose turnover in healthy subjects and patients with MAD deficiency.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2514319     DOI: 10.1007/bf01716208

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  24 in total

1.  Metabolism of d-ribose in diabetes mellitus.

Authors:  E L BIERMAN; E M BAKER; I C PLOUGH; W H HALL
Journal:  Diabetes       Date:  1959 Nov-Dec       Impact factor: 9.461

2.  The identification of ribulose and L-xylulose in human and rat urine.

Authors:  S FUTTERMAN; J H ROE
Journal:  J Biol Chem       Date:  1955-07       Impact factor: 5.157

3.  The metabolism of D-ribose in man.

Authors:  S SEGAL; J FOLEY
Journal:  J Clin Invest       Date:  1958-05       Impact factor: 14.808

4.  Studies of ribose metabolism. III. The pathway of ribose carbon conversion to glucose in man.

Authors:  H H HIATT
Journal:  J Clin Invest       Date:  1958-05       Impact factor: 14.808

5.  Paper chromatographic detection of sugars in normal and dystrophic human urines.

Authors:  W C HESS; A A WHITE
Journal:  Arch Biochem Biophys       Date:  1956-09       Impact factor: 4.013

6.  Nature and significance of pentosuria in neuromuscular disease.

Authors:  D B TOWER; E L PETERS; M A POGORELSKIN
Journal:  Neurology       Date:  1956-02       Impact factor: 9.910

7.  D-ribose inhibits DNA repair synthesis in human lymphocytes.

Authors:  G Zunica; M Marini; M A Brunelli; M Chiricolo; C Franceschi
Journal:  Biochem Biophys Res Commun       Date:  1986-07-31       Impact factor: 3.575

8.  Quantitative comparison and evaluation of utilization of parenteral administered carbohydrates.

Authors:  P U Heuckenkamp; N Zöllner
Journal:  Nutr Metab       Date:  1975       Impact factor: 4.169

9.  The effect of D-ribose infusion on serum immuno-reactive insulin and glucose concentration.

Authors:  T Steinberg; P Ortman; R Poucher; B Cochran; G Gwinup
Journal:  Metabolism       Date:  1967-01       Impact factor: 8.694

10.  alpha-Fucose inhibits human mixed-lymphocyte culture reactions and subsequent suppressor cell generation.

Authors:  J Stankova; M Rola-Pleszczynski
Journal:  Cell Immunol       Date:  1984-01       Impact factor: 4.868

View more
  15 in total

Review 1.  Dietary supplements and team-sport performance.

Authors:  David Bishop
Journal:  Sports Med       Date:  2010-12-01       Impact factor: 11.136

2.  Muscle metabolism and red cell ATP/ADP concentration during bicycle ergometer in patients with AMPD-deficiency.

Authors:  D R Wagner; J Felbel; U Gresser; N Zöllner
Journal:  Klin Wochenschr       Date:  1991-04-04

Review 3.  Clinical heterogeneity and molecular mechanisms in inborn muscle AMP deaminase deficiency.

Authors:  M Gross
Journal:  J Inherit Metab Dis       Date:  1997-06       Impact factor: 4.982

4.  Myoadenylate deaminase deficiency: successful symptomatic therapy by high dose oral administration of ribose.

Authors:  N Zöllner; S Reiter; M Gross; D Pongratz; C D Reimers; K Gerbitz; I Paetzke; T Deufel; G Hübner
Journal:  Klin Wochenschr       Date:  1986-12-15

Review 5.  Molecular biology of AMP deaminase deficiency.

Authors:  M Gross
Journal:  Pharm World Sci       Date:  1994-04-15

6.  Effects of therapeutic ribose levels on human lymphocyte proliferation in vitro.

Authors:  W Pliml; T von Arnim; C Hammer
Journal:  Clin Investig       Date:  1993-10

7.  Serum levels of glucose, insulin, and C-peptide during long-term D-ribose administration in man.

Authors:  M Gross; N Zöllner
Journal:  Klin Wochenschr       Date:  1991-01-04

8.  Ribose administration during exercise: effects on substrates and products of energy metabolism in healthy subjects and a patient with myoadenylate deaminase deficiency.

Authors:  M Gross; B Kormann; N Zöllner
Journal:  Klin Wochenschr       Date:  1991-02-26

9.  Daily supplementation of D-ribose shows no therapeutic benefits in the MHC-I transgenic mouse model of inflammatory myositis.

Authors:  William Coley; Sree Rayavarapu; Jack H van der Meulen; Ayyappa S Duba; Kanneboyina Nagaraju
Journal:  PLoS One       Date:  2013-06-13       Impact factor: 3.240

10.  Ribose Accelerates Gut Motility and Suppresses Mouse Body Weight Gaining.

Authors:  Yan Liu; Tong-Ruei R Li; Cong Xu; Tian Xu
Journal:  Int J Biol Sci       Date:  2016-04-28       Impact factor: 6.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.